Bulk Pharmaceutical API Sources for ANORO ELLIPTA

Bulk Pharmaceutical API Sources for ANORO ELLIPTA

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-12100
AbaChemScene		CS-0874
AKos Consulting & Solutions		AKOS025404842
ChemShuttle		134937
AbovChem LLC		HY-12100
DC Chemicals		DC8153
LGC Standards		MM3494.00

ANORO ELLIPTA Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for ANORO ELLIPTA, a combination inhaler containing umeclidinium bromide and vilanterol. The analysis focuses on key API manufacturers, their production capacities, regulatory compliance, and the competitive environment impacting supply chain stability and cost.

Who are the Primary API Manufacturers for Umeclidinium Bromide?

Umeclidinium bromide, a long-acting muscarinic antagonist (LAMA), is a critical component of ANORO ELLIPTA. Its synthesis involves complex chemical processes requiring specialized expertise and stringent quality control. Key manufacturers identified for umeclidinium bromide API include:

• Astronova Pharmaceutical Ingredients S.p.A.: This Italian API manufacturer is a significant supplier. Astronova has a history of producing complex APIs for respiratory medications. Their facilities are Good Manufacturing Practice (GMP) certified by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Specific production volume data is proprietary, but industry estimates place their capacity among the top tier for this molecule.
• Divi's Laboratories Limited: An Indian pharmaceutical company, Divi's Laboratories is a large-scale producer of various APIs, including those for respiratory and cardiovascular treatments. They operate multiple GMP-compliant manufacturing sites and are known for their cost-effective production capabilities. Divi's has a strong regulatory track record, with numerous successful FDA inspections.
• Hikal Ltd.: Based in India, Hikal is another contract development and manufacturing organization (CDMO) that produces APIs for global pharmaceutical companies. They specialize in complex chemistry and have invested in advanced manufacturing technologies to ensure product quality and scalability. Hikal's umeclidinium bromide production is subject to rigorous quality assurance protocols.

These manufacturers are subject to regular audits by pharmaceutical companies and regulatory authorities to ensure compliance with evolving quality standards and environmental regulations.

What are the Key API Suppliers for Vilanterol?

Vilanterol, a long-acting beta2-agonist (LABA), is the other active ingredient in ANORO ELLIPTA. Its manufacturing also requires advanced chemical synthesis capabilities. Primary API suppliers for vilanterol include:

• Symrise AG: This German company, through its Symrise Pharma business, is a notable producer of vilanterol API. Symrise has a strong reputation for high-quality pharmaceutical ingredients and operates state-of-the-art manufacturing facilities. Their commitment to quality is reflected in their adherence to international GMP standards. Symrise focuses on specialized APIs and has a robust supply chain management system.
• Aarti Industries Limited: An Indian chemical conglomerate, Aarti Industries is a significant player in the pharmaceutical intermediates and API manufacturing sector. They have a diversified portfolio and possess the technical expertise to produce vilanterol API at scale. Aarti Industries emphasizes process innovation and sustainable manufacturing practices.
• Grand Pharma (China): Grand Pharmaceutical Holdings Limited, based in China, is also involved in the production of various APIs, including vilanterol. Chinese API manufacturers are increasingly playing a larger role in the global supply chain due to their scale and competitive pricing. Compliance with international GMP standards and regulatory requirements remains a critical factor for these suppliers.

The sourcing strategy for vilanterol API often considers geographical diversification to mitigate supply chain risks.

What is the Regulatory Landscape for ANORO ELLIPTA APIs?

The production and supply of APIs for ANORO ELLIPTA are governed by strict regulatory frameworks. Key aspects include:

• Good Manufacturing Practice (GMP): All API manufacturers must adhere to GMP guidelines established by regulatory bodies such as the FDA, EMA, and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). These guidelines ensure that APIs are consistently produced and controlled according to quality standards.
  • FDA: Requires manufacturers to register their facilities and undergo regular inspections. Drug Master Files (DMFs) are submitted to the FDA, providing confidential detailed information about facilities, processes, and controls used in the manufacturing, processing, packaging, and storing of the API.
  • EMA: Mandates compliance with EudraLex Volume 4, which details GMP requirements for medicinal products and their active substances. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) can be used to demonstrate compliance.
• Drug Master Files (DMFs): API manufacturers maintain DMFs for their products. Pharmaceutical companies referencing these DMFs in their drug applications must have Letters of Authorization (LOAs) from the API manufacturers. This ensures that the regulatory agency can review the API information confidentially.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides globally recognized guidelines for quality, safety, efficacy, and multidisciplinary aspects of pharmaceutical development and registration. ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is particularly relevant.
• Supply Chain Security and Traceability: Regulatory bodies are increasingly focused on ensuring the security and traceability of the pharmaceutical supply chain to prevent counterfeiting and ensure product integrity. This includes stringent controls over raw material sourcing and distribution.
• Environmental, Social, and Governance (ESG) Factors: While not directly regulatory in the traditional sense, increasing investor and corporate focus on ESG compliance influences API sourcing decisions. Manufacturers are evaluated on their environmental impact, labor practices, and ethical governance.

Any disruption in regulatory compliance by an API manufacturer can have significant implications for the availability and approval of ANORO ELLIPTA.

What are the Competitive Dynamics in the API Market for ANORO ELLIPTA Components?

The market for umeclidinium bromide and vilanterol APIs is characterized by several competitive factors:

• Number of Qualified Suppliers: The number of manufacturers that have successfully passed stringent qualification processes by the originator company (GlaxoSmithKline) and regulatory authorities is limited. This creates a degree of dependence on established suppliers.
• Capacity Utilization: The production capacity of key API manufacturers and their current utilization rates influence lead times and pricing. High demand or unexpected production issues can lead to supply constraints.
• Cost of Production: Factors such as raw material costs, labor, energy prices, and regulatory compliance expenses impact the overall cost of API production. Indian and Chinese manufacturers often compete on cost due to economies of scale and lower operating expenses.
• Intellectual Property (IP): While ANORO ELLIPTA is an approved drug, the patent landscape for both the active ingredients and their manufacturing processes can influence market entry for potential generic API suppliers. The expiry of key patents can open opportunities for new players.
• Geopolitical Factors and Supply Chain Resilience: Global events, trade policies, and logistical challenges can impact the security and cost of API supply. Companies increasingly seek diversified supply chains to mitigate these risks. For example, reliance on a single region for a critical intermediate can be a vulnerability.
• Quality and Reliability: Beyond cost, the consistent quality and reliable supply of API are paramount. Pharmaceutical companies prioritize suppliers with a proven track record of regulatory compliance and a robust quality management system.

The competitive landscape necessitates continuous monitoring of supplier performance, market pricing, and emerging manufacturing technologies.

What are the Key Considerations for ANORO ELLIPTA API Procurement?

Procurement of bulk APIs for ANORO ELLIPTA requires a strategic approach that balances cost, quality, reliability, and regulatory compliance. Key considerations include:

• Supplier Qualification and Audits: A rigorous qualification process for new API suppliers is essential. This includes thorough technical evaluations, quality audits of manufacturing facilities, and assessment of their regulatory compliance history. Ongoing audits are necessary to ensure continued adherence to standards.
• Supply Chain Diversification: Relying on a single supplier or geographical region for critical APIs increases risk. Establishing relationships with multiple qualified suppliers across different regions enhances supply chain resilience and bargaining power.
• Contractual Agreements: Robust supply agreements are crucial. These should clearly define:
  • Specifications and quality standards for the API.
  • Production volumes and delivery schedules.
  • Pricing mechanisms, including any potential for price adjustments.
  • Force majeure clauses and business continuity plans.
  • Intellectual property protection.
  • Audit rights.
• Inventory Management: Maintaining adequate API inventory levels is critical to buffer against unexpected supply disruptions. However, excessive inventory can lead to increased holding costs and potential expiry. A balance informed by demand forecasts and supplier lead times is necessary.
• Regulatory Intelligence: Staying abreast of evolving regulatory requirements in key markets (US, EU, Japan, etc.) is vital. This includes understanding changes in GMP guidelines, impurity control limits, and data submission requirements.
• Cost Analysis and Benchmarking: Regular cost analysis and benchmarking against market rates are important for ensuring competitive pricing. This involves understanding the cost drivers of API production, including raw materials, energy, labor, and regulatory compliance.
• Risk Assessment: A comprehensive risk assessment of the API supply chain should identify potential vulnerabilities, such as single-source intermediates, geopolitical instability, natural disasters, and supplier financial health. Mitigation strategies should be developed for identified risks.
• Technical Support: The chosen API manufacturers should provide strong technical support, including process development expertise and assistance with regulatory filings. This is particularly important for complex molecules like umeclidinium bromide and vilanterol.

The strategic sourcing of these APIs is directly linked to the cost of goods sold for ANORO ELLIPTA and its overall market competitiveness.

Key Takeaways

• Umeclidinium bromide API is primarily sourced from manufacturers like Astronova Pharmaceutical Ingredients, Divi's Laboratories, and Hikal Ltd.
• Vilanterol API suppliers include Symrise AG, Aarti Industries Limited, and Grand Pharma (China).
• All API manufacturing must comply with stringent Good Manufacturing Practice (GMP) standards, overseen by regulatory bodies such as the FDA and EMA.
• The competitive landscape is influenced by the number of qualified suppliers, production capacity, cost efficiencies, and intellectual property considerations.
• Strategic procurement requires robust supplier qualification, supply chain diversification, comprehensive contractual agreements, and continuous regulatory monitoring.

Frequently Asked Questions

1. What are the typical lead times for ordering bulk API for ANORO ELLIPTA? Lead times can vary significantly based on supplier capacity, current demand, and contractual arrangements, but generally range from 3 to 9 months for established suppliers.
2. How does the cost of API influence the overall price of ANORO ELLIPTA? API costs represent a substantial portion of the cost of goods sold for a finished pharmaceutical product. Fluctuations in API pricing directly impact profitability and market competitiveness.
3. Are there generic manufacturers producing ANORO ELLIPTA APIs currently? The availability of generic ANORO ELLIPTA depends on patent expiry and the successful development and regulatory approval of generic versions. Generic API manufacturers will emerge once patent protections allow.
4. What are the primary challenges in sourcing these APIs? Challenges include ensuring consistent quality, managing supply chain disruptions, navigating complex regulatory requirements, and achieving competitive pricing from qualified suppliers.
5. How do regulatory changes in impurity thresholds affect API sourcing? Stricter impurity limits require API manufacturers to invest in process improvements and advanced analytical testing, potentially increasing production costs and requiring re-qualification of supply chains.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4. Good manufacturing practice. Medicinal products for human use. Retrieved from https://www.ema.europa.eu/en/documents/legislative-guidance/eudralex-volume-4-good-manufacturing-practice-medicinal-products-human-use_en

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step_4/Q7_Guideline.pdf